The use of FLT3 inhibitors in AML

(4:47)

Optimizing Use of FLT3 Inhibitor Therapy for AML

(4:5)

Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML

(2:8)

A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML

(1:30)

Second-Generation FLT3 Inhibitors in AML

(3:18)

Combining menin/FLT3/BCL2 inhibition as a treatment approach in FLT3/NPM1 double mutated AML

(2:29)

An overview of the safety profile of FLT3 inhibitors in AML

(2:40)

FLT3 inhibitors: revolutionizing the management of AML

(2:38)

The value of FLT3 inhibitors in AML and focus for future trial designs

(1:12)

Role of FLT3 Inhibitors and Other Novel Agents in AML

(20:29)

Emerging FLT3 Inhibitors in AML

(5:49)

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

(9:39)

Novel FLT3 inhibitors for AML

(3:27)

The Role of FLT3 Inhibitors in Acute Myeloid Leukemia

(2:7)

Novel potent and selective FLT3 inhibitors

(2:19)

Optimizing the use of FLT3 inhibitors in AML: sequencing, post-transplant maintenance \u0026 more

(1:59)

COVALENT-103: investigating BMF-500, an oral covalent FLT3 inhibitor, in acute leukemias

(1:54)

FLT3 inhibitors for treating AML

(1:28)

FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia

(39:50)